Overview
Determination of specific molecular breath patterns by secondary electrospray ionisation mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation. Furthermore, breath patterns will be assessed for correlation and association to clinical outcomes and treatment.
Eligibility
Inclusion Criteria:
- Informed consent
- age >= 18 years
- staged according to GOLD recommendations
- GOLD stage 2-4, risk groups A-D
- hospitalization due to COPD exacerbation
- subjects adherent to triple inhalational therapy (beta-2-sympathomimetics, anticholinergics, steroids)
- suitable for follow-up assessment
- <48 hours after initiation of antibiotic therapy or systemic steroid therapy
Exclusion Criteria:
- physical or intellectual impairment precluding informed consent or protocol adherence
- known pregnancy
- congenital defects with direct impact on central metabolism e.g. amino acid metabolism defect
- uncontrolled diabetes (e.g. HbA1c >11% or Glc >20mmol/l).
- acute or chronic pulmonary disease other than COPD
- renal failure or renal replacement therapy (GFR < 15 mL/min)
